vantavo (previously alendronate sodium and colecalciferol, msd)
n.v. organon - alendronsyre, colecalciferol - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af postmenopausal osteoporose hos patienter med risiko for vitamin d-insufficiens. vantavo reducerer risikoen for vertebrale og hoftebrud. behandling af postmenopausal osteoporose hos patienter, der ikke får d-vitamin d-tilskud, og er i risiko for d-vitamin d-insufficiens. vantavo reducerer risikoen for vertebrale og hoftebrud.
tevimbra
novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastiske midler - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.
mycamine
astellas pharma europe b.v. - micafungin - candidiasis - antimykotika til systemisk brug - mycamine er indiceret til:voksne, unge ≥ 16 år og elderlytreatment af invasiv candidiasis behandling af øsofagus candidiasis hos patienter, for hvem intravenøs behandling er hensigtsmæssig forebyggelse af candida infektioner hos patienter, der gennemgår allogen hæmatopoietisk stamcelle transplantation eller patienter, der forventes at få neutropeni (absolut neutrophil count < 500 celler/µl) for 10 eller flere dage. børn (herunder nyfødte) og unge < 16 år agetreatment af invasiv candidiasis. forebyggelse af candida infektioner hos patienter, der gennemgår allogen hæmatopoietisk stamcelle transplantation eller patienter, der forventes at få neutropeni (absolut neutrophil count < 500 celler/µl) for 10 eller flere dage. beslutningen om at bruge mycamine bør tage hensyn til en potentiel risiko for udvikling af tumorer i leveren. mycamine bør derfor kun anvendes, hvis andre antimykotika ikke er hensigtsmæssige.
ibandronat "stada" 150 mg filmovertrukne tabletter
stada arzneimittel ag - natriumibandronatmonohydrat - filmovertrukne tabletter - 150 mg
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - midler til dermatitis, undtagen kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
controloc control
takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.
nexium control
glaxosmithkline dungarvan limited - esomeprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - nexium control er indiceret til kortvarig behandling af reflukssymptomer (f.eks. halsbrand og syreregurgitation) hos voksne.
pantecta control
takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.
pantoloc control
takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.
somac control
takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.